The use of fructose in the dietary treatment of diabetes has a very long history [1] , but it remains unsolved whether fructose has any place in the dietary treatment of insulin-dependent diabetics today. The saccharine and cyclamate ban in U.S.A. has provoked a renewed interest in the use of fructose as a sweetener for diabetics [2, 3] , but still doubt and hesitation prevail. The dietary treatment of insulindependent diabetics is based on a daily supply of significant amounts of slowly absorbed carbohydrates (starch) in a meal pattern, which is repeated from day to day in order to diminish the tendency to hyperglycaemia and or hypoglycaemia between meals. The putative place of fructose in such a dietary scheme should be as a sweetener, i. e. as a substitute for sucrose, not for starch. Because fructose as a sweetener has to be taken in approximately the same amounts as sucrose one problem has been whether fructose causes a smaller rise in blood glucose concentration than sucrose. Such a beneficial effect of fructose has certainly been found [4] .
So why do we not recommend fructose? Fructose is very rapidly metabolized in the liver to glucose and lactate in a way which is independent of insulin [5] . Even in the starved state fructose may turn the liver from a lactate clearing organ to a lactate producing organ. The proportion of fructose which is converted to lactate in the liver is greatly increased by anoxia and a concomitant high glucose concentration (Table  1) . Thus fructose metabolism may induce lactate acidosis when there is already insufficient hepatic clearance of peripherally produced lactate. Such an effect has been shown in humans after intravenous administration of fructose and several warnings against this fructose effect have been given in the past 10 years [7, 8, 9] . In fructose infusion studies the arterial concentration of fructose has been about 5 mmol/1 [10, 11, 12] . The effect of fructose on liver metabolism is linearly dependent on the fructose concentration in the low concentration range [13] , because of a relatively low affinity for transport across the plasma membrane [14] . Therefore the fructose effects after peroral intake must be anticipated to be strongly dependent on the portal fructose concentration, which has not been measured in humans. However, the following calculation can illustrate what happens after a significant peroral intake of fructose in humans.
If 60 g of fructose (330 mmol) are taken perorally within a short time (e. g. 10 min), absorption will be complete in about 100m in. Because fructose in humans seems to be absorbed and delivered intact to the portal circulation [15] the average fructose concentration in the absorption period will be about 3.3 mmol/1, provided the portal flow is 1000 ml/min. If the liver weight is 1500 g the average rate of fructose conversion should be 2.2 ptmol/min per g liver, provided no fructose passes completely through the liver. The hepatic extraction of fructose is indeed high [11, 12] in that there are very low (0.2 mmol/1) peripheral fructose concentrations after peroral fructose intake [16] . Thus the average rate of fructose uptake in liver can be estimated to be about 1.75 ,umol/min per g liver. This relationship between concentration and splanchnic hepatic fructose uptake has been confirmed in fructose infusion experiments [11] . Further, it has been shown that 30 g fructose given perorally, increases the rate of ethanol oxidation by about 50% [17] . From this observation two conclusions can bc drawn: first, that the major part of fructose given perorally must be metabolized in the same organ as ethanol, namely in the liver, and second, that the rate of fructose conversion to glucose and lactate must be about 1.7 btmol/min/g liver since in human fructose infusion experiments and pig liver perfusion experiments this rate of fructose metabolism increases the rate of ethanol oxidation by 50-80% [11, 18] . Thus it can be concluded that the rate of fructose metabolism in liver is of the same order of magnitude after peroral intake and after infusion of about 1 g fructose/kg/h. Such a rate of fructose metabolism elicits signifi-O012-186X/79/0017/0001/$01.00 cant disturbances in the metabolism of perfused livers from rats. For instance, in perfused rat liver the concentration of energy rich phosphates, in particular ATP, is decreased by about 50% [14] , and in a 10-15min period following initiation of fructose metabolism the concentration of inorganic phosphate in the extra mitochondrial compartment decreases to very low values [19] . The concentration of inorganic phosphate decreases to very low values because of accumulation of fructose 1-phosphate in concentrations which are at least 10 times higher than the concentration of other phosphorylated intermediates [20, 21] . The metabolic consequences of fructose metabolism thus are: a nearly quantitative interconversion of fructose to glucose + lactate, which goes on very rapidly, and which is accompanied by an increase in the intracellular concentration of fructose 1-phosphate and by a decrease in inorganic phosphate concentration. This leaves the liver in a disturbed metabolic state, distinguished by a decrease in the content of ATP, a decreased concentration of total adenine nucleotides, a decrease in the ability of the liver to take up lactate, and with a series of changes in enzymatic regulation (see e.g. [6] ). The increased rate of degradation of adenine nucleotides is reflected in a stocheoimetrical increase in the rate of uric acid (or allantoin) formation [22, 23] . For the diabetic the effect of fructose on blood glucose, uric acid production, triglyceride synthesis and ketogenesis are of major importance. The fate of carbon from fructose ingested perorally has not yet been quantitatively investigated. However, in experiments with liver catheterization [11, 12] or with 14C-labelled fructose [24] in humans given fructose intravenously it appears that only a few percent of fructose is directly oxidized by the liver to CO2 and water, and about 30% is accounted for by glucose measured in the blood. However, at the same time the rate of net glucose production by the liver is decreased or only slightly increased [12, 24] , in rare cases leading to overt hypoglycaemia [25] , due to accumulation of glycogen in liver [26, 27] . The biochemical mechanism by which fructose induces a large net rate of glycogen formation is well elucidated and is based upon an inhibition of phosphorylase a by the high fructose 1-phosphate concentration, by the very low concentration of Pi, concomitant with a decreased rate of cyclic AMP production the magnitude of which depend on the level of ATP in the liver tissue [28] . Since the low Pi concentration, the high fructose 1-phosphate concentration, and the decrease in ATP, are all involved in the mechanisms of the untoward effects of fructose, the proof of the existence of untoward effects of fructose given perorally may be found in the explanation of its beneficial effect on blood glucose.
Fructose does not inhibit the rate of nonesterified fatty acid (NEFA) uptake in liver or increase its oxidation to CO2 and water significantly, but rapidly decreases the rate of ketone body formation to very low values, and thus the bulk of NEFA taken up must be converted into triglyceride [29] . Such an effect has evidence in the clinical literature [see 30], but conflicting results have been published since a decreased rate of lipolysis in adipose tissue may result in a lowering effect of fructose on plasma triglyceride in normal persons. In the poorly regulated diabetic, the lack of insulin may lead to an exaggaration of the fructose induced rise in plasma triglyceride concentration, but as a whole, we do not know very much about the effects of fructose on blood glucose and triglyceride concentrations in diabetics in different states of regulation. It is reasonable to imagine that when insulin is lacking fructose metabolism will give rise to an increased rate of production of plasma glucose and triglyceride as compared to conditions with normo-or hyperinsulinaemia [31] . On the other hand if a diabetic takes a long-drink containing fructose in order to cope with hypoglycaemic symptoms this may well elicit even more severe hypoglycaemic episodes. This is because fructose does not give rise to any significant increase in blood glucose concentration and partially blocks the ability of the patient to provide glucose from liver glycogen under conditions with hyperinsulinaemia.
It is not easy to accept that the antiketogenic action of fructose [32] should be beneficial for the diabetic. Under conditions with proper insulin treatment, and starvation ketosis, any carbohydrate (also slowly absorbed carbohydrates) will counteract the tendency to ketosis. Under conditions with deficient insulin treatment, fructose administration will cause a decrease in the conversion of NEFA to ketone bodies, and a concomitant decrease in the conversion of lactate to glucose. Thus, the rate of net acid production by the liver may well be increased due to the net production of lactate from fructose and the glucose production will continue with fructose as the carbon source. The net outcome will be continued hyperglycaemia, hyperlactataemia and increased triglyceride synthesis.
We do not know anything about the effects of an increased turnover of adenine nucleotides in patients over longer periods, but it seems unreasonable to increase the rate of uric acid production in patients with decreased renal function, e.g., with diabetic nephropathy.
In genetically selected rats fructose, in contrast to starch, leads to the development of diabetes including diffuse glomerulosclerosis [33] . The finding that fructose induces a reduction in insulin-binding affinity to monocytes and a decrease in insulin sensitivity in healthy humans [34] may prove significant for the pathogenic action of sugar in diabetes.
Thus, because many questions, especially on the quantitative aspects of fructose metabolism in relation to the state of regulation in diabetics and on its role in the pathogenesis of diabetes remain unanswered it should be considered wise not to promote the use of fructose as a sweetener for diabetics on a large scale.
